For instance, ERK1 primarily mediates cisplatin-induced apoptosis, while inhibiting ERK2 leads to increased ERK1 activity, thereby, enhancing cancer cells' responsiveness to cisplatin treatment [12]. The gene discussed is MAPK3; the disease is cancer.